Ecnoglutide

PreclinicalPeptide

HHangzhou Sciwind Biosciences Co., Ltd.

Ecnoglutide is one of 2 small molecule programs targeting Overweight and/or Obesity. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Overweight And/or ObesityRecruiting

Overweight And/or ObesityPreclinical

Recruiting

Competition

Competitive Landscape

1 competitor in Overweight And/or Obesity

#DrugCompanyPhaseTrials

Hdm1005

HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Phase 1

1 2

Ecnoglutide

HHangzhou Sciwind Biosciences Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

PreclinicalRecruiting

Overweight And/or Obesity

NCT07243171

Clinical

Trials by Indication[1]

Efficacy2 trials

A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM

Completed·HHangzhou Sciwind Biosciences Co., Ltd.·Phase 3·NCT05680129·623 enrolled

A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients

Completed·HHangzhou Sciwind Biosciences Co., Ltd.·Phase 3·NCT05680155·211 enrolled

Overweight1 trial

A Phase 3 Study to Evaluate the Efficacy of XW003 in Adults With Overweight or Obesity

Completed·HHangzhou Sciwind Biosciences Co., Ltd.·Phase 3·NCT05813795·664 enrolled

Adult1 trial

XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults

Completed·SSciwind Biosciences APAC CO Pty. Ltd.·Phase 1·NCT05184322·87 enrolled

Overweight and/or Obesity1 trial

A Multicenter, Multiple-dose Escalation, Randomized, Double-blind, Placebo-controlled Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity

Recruiting·HHangzhou Sciwind Biosciences Co., Ltd.·Preclinical·NCT07243171·126 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Ecnoglutide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ecnoglutide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ecnoglutide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hangzhou Sciwind Biosciences Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Peptide[2]
Highest Phase: Preclinical[1]
Company: HHangzhou Sciwind Biosciences Co., Ltd.

Ecnoglutide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Efficacy2 trials

Overweight1 trial

Adult1 trial

Overweight and/or Obesity1 trial

References

Drug Info

Quick Facts

Related News